We are delighted to share that HighLight Capital (HLC), a private equity firm focusing on venture and growth investments across healthcare and consumer health sectors in China, held the final close of its flagship HLC USD Fund IV at US$550 million. To date, HLC has raised close to $1 billion across its USD and RMB funds.
HLC USD Fund IV takes the firm’s total AUM to over US$3.8 billion and underscores HLC’s focus on the Chinese life science, healthcare, consumer wellness and material science spaces. HLC continues to build a successful portfolio across investment stages and sub-sectors that can achieve liquidity regardless of business cycles. Alongside the firm’s existing USD and RMB franchises, HLC USD Fund IV will enable HLC to further capitalize on the current valuation landscape in China.
Asante Capital Group served as the global exclusive placement agent for the HLC USD Fund IV and Cooley acted as the legal counsel.
About HighLight Capital
Founded in 2014, HLC is an investment firm dedicated to creating long term values through promoting technology innovations. Empowered by deep knowledge in chemical, biological and material sciences, and leveraging the firm’s proprietary industry research and comprehensive enablement services, HLC strives to invest in companies that boost manufacturing efficiency and improve human wellness.
About Asante
Asante Capital Group is a leading independent private equity placement and advisory group. Founded in 2010, the firm has offices in London, New York City, Hong Kong, and Munich. The team of over 70 professionals has advised on over $80 billion of successful private capital raisings across the globe, raising capital from North American, European, Middle East and Asia-Pacific-based investors. Asante specializes in GP advisory and fundraising support across primary, direct and secondary investments.
